ArticleGut pathogens2026
Gram-negative gut colonization in children newly diagnosed with malignancy: microbiology, antimicrobial resistance pattern, and clinical implications.
Article in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Enterobacterales (CRE) pose significant treatment difficulties owing to their high levels of antibiotic resistance. This study investigated the gut colonization rates of carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) and extended-spectrum β-lactamase-producing (ESBL) gram-negative bacteria (GNB). Moreover, this study evaluated the antibiotic susceptibility profiles of CP-CRE and ESBL-producing Gram-negative bacteria. It also examines the potential infectious complications that may arise in pediatric patients recently diagnosed with cancer.
methodsThis prospective cohort study was conducted at a referral teaching oncology hospital in Shiraz, Iran. Fecal samples were collected at three time points: within 48-72 h of hospitalization, at the end of the first chemotherapy session, and during the next admission. The first sample identified cases of community-acquired colonization, whereas the second and third samples assessed hospital-acquired colonization by gram-negative bacteria. The infectious outcomes examined in this study included neutropenic enterocolitis (typhlitis), a life-threatening condition, and bloodstream infection.Antimicrobial susceptibility testing was performed for all gram-negative isolates using Clinical and Laboratory Standards Institute (CLSI)-standardized disk diffusion methods. Extended-spectrum β-lactamase (ESBL) production was screened and confirmed phenotypically, according to the CLSI criteria. In a subset of Escherichia coli (E. coli) isolates, polymerase chain reaction (PCR) was used to detect key β-lactamase and carbapenemase genes (blaCTX-M, blaTEM, blaSHV, blaOXA-48, blaNDM, and blaKPC).
resultsEighty-one patients with a median age of 6.0 ± 0.49 years and a male: female ratio of 1.25 were included. 57 (70%) patients had community-acquired (CA) colonization with GNB, whereas eight (10%) had hospital-acquired (HA) colonization. E. coli and Klebsiella spp. were the most common pathogens in both colonization groups. In vitro susceptibility testing showed that colistin, amikacin, and carbapenems had the highest activity against the isolates. ESBL-producing GNB were detected in 91/157 (58%) fecal samples, and CP-CRE was detected in 23/157 (14.6%) samples. Twelve (21%) CA colonizers developed infectious outcomes.
conclusionsThe high incidence of CP-CRE colonization underscores the urgent need to monitor and control the spread of these highly resistant bacteria among newly diagnosed pediatric cancer patients in oncology settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.